Stakeholders advocating for cannabidiol (CBD) have crossed a second important hurdle as a preliminary evaluation of the substance by the World Health Organization (WHO) in Vienna last week produced positive findings.  “This round has ended up favorably, but the critical review of CBD will happen in May,” said Boris Baňas, board member at the European Industrial Hemp Association (EIHA).  The next review is expected at WHO’s 40th Expert Committee on Drug Dependence (ECDD) meeting in May or June, 2018.  


Source: HempToday -

hemp news


The following companies supported a campaign backing the EIHA-FAAT effort before WHO: Bluebird Botanicals, Buddingtech, CannaWell, CBD life UK, CBD oils UK,, Deep Nature Project,, Hemp and humanity, HempConsult GmbH, Hempflax, Hempire Ltd.,, Hempura, MCU Botanicals, MeetHarmony, MH medical hemp GmbH.